STOCK TITAN

Eiger BioPharmaceuticals Inc - EIGR STOCK NEWS

Welcome to our dedicated news page for Eiger BioPharmaceuticals (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eiger BioPharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eiger BioPharmaceuticals's position in the market.

Rhea-AI Summary
Eiger BioPharmaceuticals, Inc. and AnGes, Inc. have received marketing approval for Zokinvy in Japan, a treatment for Hutchinson-Gilford progeria syndrome and processing deficient progeroid laminopathy. Clinical trial data showed that Zokinvy extended life by an average of 4.3 years in children and young adults with HGPS. The approval was based on positive results demonstrating that Zokinvy lowered the risk of death in children by 72%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
-
Rhea-AI Summary
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) announced a 1-for-30 reverse stock split to regain compliance with the minimum bid price requirement of $1.00 per share on The Nasdaq Global Market. The reverse stock split reduces outstanding shares from 44.4 million to approximately 1.5 million shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2704.88%
Tags
none
-
Rhea-AI Summary
Cutera, Inc. (Nasdaq: CUTR) announces the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will lead legal, compliance, intellectual property, and human resources functions, bringing over two decades of legal experience in the life sciences industry. The appointment reflects Cutera's commitment to operational excellence, customer support, and growth of the AviClear franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
management
Rhea-AI Summary
Cutera, Inc. (Nasdaq: CUTR) announces the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will lead legal, compliance, intellectual property, and human resources functions, bringing over two decades of legal experience in the life sciences industry. The appointment reflects Cutera's commitment to operational excellence, customer support, and growth of the AviClear franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
management
-
Rhea-AI Summary
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) reports Q3 2023 financial results and business update, focusing on avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, discontinuation of peginterferon lambda study, and cash runway extension. Key financial figures include a total revenue of $3.2 million, a net loss of $18.0 million, and a cash position of $39.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.61%
Tags
earnings
-
Rhea-AI Summary
Eiger BioPharmaceuticals discontinues Phase 3 study of peginterferon lambda due to safety concerns
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.58%
Tags
clinical trial
Rhea-AI Summary
Eiger BioPharmaceuticals CEO to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences
-
Rhea-AI Summary
Eiger BioPharmaceuticals reported financial results for Q2 2023 and provided a business update. They are focusing on avexitide in metabolic diseases, particularly post-bariatric hypoglycemia (PBH) and other forms of hyperinsulinemic hypoglycemia (HH). They also plan to develop avexitide for congenital hyperinsulinism. The company achieved net revenue of $4.6 million in Q2 2023. They have reduced their workforce by 25% and expect their cash runway to extend into Q4 2024. David Apelian has been appointed as the CEO. The company had a cash position of $53.6 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
earnings
-
Rhea-AI Summary
Eiger BioPharmaceuticals will focus on advancing avexitide in hyperinsulinemic hypoglycemia indications, while evaluating strategic partnering options for its virology assets. A 25% reduction in workforce and a reduction in out-of-pocket spending are expected to extend the cash runway to Q4 2024. David Apelian has been appointed as the CEO. Avexitide has shown proof-of-concept in Phase 2 trials for post-bariatric hypoglycemia and has FDA alignment on Phase 3 endpoints. The company is actively engaged in discussions with potential partners for its late-stage assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.2%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.2%
Tags
conferences
Eiger BioPharmaceuticals Inc

Nasdaq:EIGR

EIGR Rankings

EIGR Stock Data

7.37M
1.27M
11.8%
43.86%
2.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Palo Alto

About EIGR

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.